Axogen Inc (AXGN)

$32.85 +4.52 (15.95%)
Market Cap 1.28B
Revenue (ttm) 187.34M
Net Income (ttm) -9.96M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -5.32%
Debt to Equity Ratio 0.40
Volume 3,164,400
Avg Vol 870,804
Day's Range N/A - N/A
Shares Out 46.12M
Stochastic %K 76%
Beta 1.06
Analysts Strong Sell
Price Target $29.12

Company Profile

Axogen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral...

Industry: Medical Devices
Sector: Healthcare
Phone: 386 462 6800
Fax: 386 462 6801
Address:
13631 Progress Boulevard, Suite 400, Alachua, United States
AtomicAIerts
AtomicAIerts Dec. 5 at 9:58 AM
$AXGN AtomicAlerts Scalp Alert Direction: SHORT Entry: $32.86 TP1: $32.16 | TP2: $31.46 | TP3: $30.76 Stop Loss: $33.46 👉 https://atomicalerts.com
0 · Reply
Iightning
Iightning Dec. 5 at 5:16 AM
1ightning® Premium Options Alert (Actionable) Ticker: $AXGN Contract: Dec 19 $35C Entry: 1.48 Exit: 1.93 Return: +30.94% ROI Unlock VIP Access → https://1ightning.com
0 · Reply
Biobrocker12
Biobrocker12 Dec. 4 at 11:27 PM
$AXGN got the approval! I hope you like the free play $18->$33.50
0 · Reply
Iightning
Iightning Dec. 4 at 11:04 PM
1ightning® Premium Options Alert (Actionable) Ticker: $AXGN Contract: Dec 19 $35C Entry: 1.48 Exit: 1.93 Return: +30.94% ROI Unlock VIP Access → https://1ightning.com
0 · Reply
Doozio
Doozio Dec. 4 at 9:54 PM
$AXGN speaking of pullbahhhhhcks. All da way up da Roger YO go! It’s gonna get NUTX DAVE wen they all SEZL.
0 · Reply
JarvisFlow
JarvisFlow Dec. 4 at 7:39 PM
Jefferies has updated their rating for Axogen ( $AXGN ) to Buy with a price target of 36.
0 · Reply
CharlieeMungerTWITS
CharlieeMungerTWITS Dec. 4 at 7:04 PM
$AXGN GO GO GO!!!!
0 · Reply
JarvisFlow
JarvisFlow Dec. 4 at 6:03 PM
Lake Street updates rating for Axogen ( $AXGN ) to Buy, target set at 30 → 40.
0 · Reply
LuckEtradER
LuckEtradER Dec. 4 at 5:32 PM
$AXGN 🥰
0 · Reply
RunnerSignals
RunnerSignals Dec. 4 at 4:54 PM
Midday Buzz $SNCR $PATH $AXGN $ASTS $NUTX lighting up the trackers today. Deals approvals buybacks and momentum all colliding. Something big is brewing… worth a deeper look https://stocksrunner.com/news/2025-12-04-top-gainers-buzz-stocks-up-today-stock-market-movers
0 · Reply
Latest News on AXGN
Axogen Announces FDA Approval of Biologics License Application for AVANCE® (acellular nerve allograft–arwx)

Dec 3, 2025, 8:01 PM EST - 1 day ago

Axogen Announces FDA Approval of Biologics License Application for AVANCE® (acellular nerve allograft–arwx)

FDA approves Axogen's nerve repair graft

Dec 3, 2025, 6:53 PM EST - 1 day ago

FDA approves Axogen's nerve repair graft

Avance Nerve Graft FDA Verdict Approaches, Why Investors Are Watching Axogen

Dec 1, 2025, 12:33 PM EST - 3 days ago

Avance Nerve Graft FDA Verdict Approaches, Why Investors Are Watching Axogen

Wasatch Micro Cap Value Fund Q3 2025 Contributors And Detractors

Nov 5, 2025, 2:19 PM EST - 4 weeks ago

Wasatch Micro Cap Value Fund Q3 2025 Contributors And Detractors

BELFB LMB PMTS WLDN

Axogen, Inc. (AXGN) Q3 2025 Earnings Call Transcript

Oct 29, 2025, 2:26 PM EDT - 5 weeks ago

Axogen, Inc. (AXGN) Q3 2025 Earnings Call Transcript

Axogen, Inc. Reports Third Quarter 2025 Financial Results

Oct 29, 2025, 7:00 AM EDT - 5 weeks ago

Axogen, Inc. Reports Third Quarter 2025 Financial Results

Axogen, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – AXGN

Oct 1, 2025, 12:30 PM EDT - 2 months ago

Axogen, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – AXGN

AXGN Investors Have Opportunity to Join Axogen, Inc. Fraud Investigation with the Schall Law Firm

Oct 1, 2025, 10:50 AM EDT - 2 months ago

AXGN Investors Have Opportunity to Join Axogen, Inc. Fraud Investigation with the Schall Law Firm

Axogen Provides Update on FDA Review Timeline for Avance Nerve Graft

Aug 25, 2025, 6:40 AM EDT - 3 months ago

Axogen Provides Update on FDA Review Timeline for Avance Nerve Graft

Axogen: Broad Range Of Outcomes Still Present, Opting To Remain Sidelined

Aug 12, 2025, 5:17 AM EDT - 4 months ago

Axogen: Broad Range Of Outcomes Still Present, Opting To Remain Sidelined

Axogen (AXGN) Q2 Revenue Jumps 18%

Aug 5, 2025, 6:43 PM EDT - 4 months ago

Axogen (AXGN) Q2 Revenue Jumps 18%

Axogen, Inc. (AXGN) Q2 2025 Earnings Call Transcript

Aug 5, 2025, 1:15 PM EDT - 4 months ago

Axogen, Inc. (AXGN) Q2 2025 Earnings Call Transcript

Axogen, Inc. to participate at the Canaccord Genuity 45th Annual Growth Conference

Jul 29, 2025, 4:10 PM EDT - 4 months ago

Axogen, Inc. to participate at the Canaccord Genuity 45th Annual Growth Conference

Axogen, Inc. to report 2025 second quarter financial results on August 5, 2025

Jul 22, 2025, 4:05 PM EDT - 4 months ago

Axogen, Inc. to report 2025 second quarter financial results on August 5, 2025

Axogen, Inc to Participate at Goldman Sachs Global Healthcare Conference

May 28, 2025, 8:00 AM EDT - 6 months ago

Axogen, Inc to Participate at Goldman Sachs Global Healthcare Conference

Axogen, Inc. (AXGN) Q1 2025 Earnings Call Transcript

May 9, 2025, 3:21 PM EDT - 7 months ago

Axogen, Inc. (AXGN) Q1 2025 Earnings Call Transcript

Axogen, Inc. Reports 2025 First Quarter Financial Results

May 8, 2025, 7:05 AM EDT - 7 months ago

Axogen, Inc. Reports 2025 First Quarter Financial Results

Axogen, Inc. to report 2025 first quarter financial results on May 8, 2025

Apr 24, 2025, 8:04 AM EDT - 8 months ago

Axogen, Inc. to report 2025 first quarter financial results on May 8, 2025

Axogen, Inc. (AXGN) Q4 2024 Earnings Call Transcript

Feb 25, 2025, 1:58 PM EST - 10 months ago

Axogen, Inc. (AXGN) Q4 2024 Earnings Call Transcript

Axogen, Inc. To Host Analyst & Investor Day on March 4th

Feb 25, 2025, 7:10 AM EST - 10 months ago

Axogen, Inc. To Host Analyst & Investor Day on March 4th

Axogen, Inc. to report 2024 fourth quarter and full year financial results on February 25, 2025

Feb 11, 2025, 4:58 PM EST - 10 months ago

Axogen, Inc. to report 2024 fourth quarter and full year financial results on February 25, 2025

Axogen Announces New VP of Operations and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jan 10, 2025, 5:00 PM EST - 11 months ago

Axogen Announces New VP of Operations and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Axogen: Well Placed To Capitalize Growth At Higher Multiples

Jan 6, 2025, 8:01 PM EST - 11 months ago

Axogen: Well Placed To Capitalize Growth At Higher Multiples

Axogen, Inc (AXGN) Q3 2024 Earnings Call Transcript

Nov 9, 2024, 9:53 AM EST - 1 year ago

Axogen, Inc (AXGN) Q3 2024 Earnings Call Transcript

Axogen Completes Submission of Biologics License Application to U.S. Food and Drug Administration for Avance Nerve Graft®

Sep 6, 2024, 7:00 AM EDT - 1 year ago

Axogen Completes Submission of Biologics License Application to U.S. Food and Drug Administration for Avance Nerve Graft®

Apple, Inc. (AXGN) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 2:10 PM EDT - 1 year ago

Apple, Inc. (AXGN) Q2 2024 Earnings Call Transcript

Axogen, Inc. Announces New Leadership Appointments

Aug 8, 2024, 7:05 AM EDT - 1 year ago

Axogen, Inc. Announces New Leadership Appointments

Axogen, Inc. to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024

Jul 23, 2024, 7:00 AM EDT - 1 year ago

Axogen, Inc. to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024

Company Reports Inducement Grants to Non-Executive New Employee Under Nasdaq Listing Rule 5635(C)(4)

Jul 1, 2024, 7:00 AM EDT - 1 year ago

Company Reports Inducement Grants to Non-Executive New Employee Under Nasdaq Listing Rule 5635(C)(4)

Axogen, Inc Announces Full Launch of Avive+ Soft Tissue Matrix™

Jun 24, 2024, 7:00 AM EDT - 1 year ago

Axogen, Inc Announces Full Launch of Avive+ Soft Tissue Matrix™

Axogen Processing Center (APC) Celebrates its Opening with Ohio Leaders in Vandalia

May 28, 2024, 4:30 PM EDT - 1 year ago

Axogen Processing Center (APC) Celebrates its Opening with Ohio Leaders in Vandalia

AxoGen, Inc. (AXGN) Q1 2024 Earnings Call Transcript

May 5, 2024, 1:21 AM EDT - 1 year ago

AxoGen, Inc. (AXGN) Q1 2024 Earnings Call Transcript

Axogen, Inc Reports First Quarter 2024 Financial Results

May 2, 2024, 7:00 AM EDT - 1 year ago

Axogen, Inc Reports First Quarter 2024 Financial Results

Axogen Announces First Surgical Implants of Avive+ Soft Tissue Matrix™

Apr 29, 2024, 4:50 PM EDT - 1 year ago

Axogen Announces First Surgical Implants of Avive+ Soft Tissue Matrix™

Axogen, Inc. to Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024

Apr 16, 2024, 7:00 AM EDT - 1 year ago

Axogen, Inc. to Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024

AxoGen, Inc. (AXGN) Q4 2023 Earnings Call Transcript

Mar 5, 2024, 11:03 AM EST - 1 year ago

AxoGen, Inc. (AXGN) Q4 2023 Earnings Call Transcript

Axogen, Inc Reports 2023 Fourth Quarter and Full-Year Financial Results

Mar 5, 2024, 7:00 AM EST - 1 year ago

Axogen, Inc Reports 2023 Fourth Quarter and Full-Year Financial Results

Axogen, Inc. to Report 2023 Fourth Quarter and Full-Year Financial Results on March 5, 2024

Feb 13, 2024, 4:30 PM EST - 1 year ago

Axogen, Inc. to Report 2023 Fourth Quarter and Full-Year Financial Results on March 5, 2024

Company Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Feb 2, 2024, 4:15 PM EST - 1 year ago

Company Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Axogen, Inc. Announces Positive Topline Results from REPOSE, a Prospective, Randomized Clinical Trial of Axoguard Nerve Cap

Jan 18, 2024, 5:00 PM EST - 2 years ago

Axogen, Inc. Announces Positive Topline Results from REPOSE, a Prospective, Randomized Clinical Trial of Axoguard Nerve Cap

Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2023

Jan 4, 2024, 4:45 PM EST - 2 years ago

Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2023

Axogen Announces Plan for Leadership Transition with CEO Karen Zaderej to Retire from Company by January 2025

Jan 4, 2024, 4:40 PM EST - 2 years ago

Axogen Announces Plan for Leadership Transition with CEO Karen Zaderej to Retire from Company by January 2025

Axogen Announces Promotions on Research and Development Team

Jan 4, 2024, 4:35 PM EST - 2 years ago

Axogen Announces Promotions on Research and Development Team

Axogen, Inc. Appoints Kathy Weiler to its Board of Directors

Dec 26, 2023, 4:15 PM EST - 2 years ago

Axogen, Inc. Appoints Kathy Weiler to its Board of Directors

Axogen Announces Transition of Finance Team Leadership

Dec 6, 2023, 7:00 AM EST - 2 years ago

Axogen Announces Transition of Finance Team Leadership

Company Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dec 1, 2023, 5:00 PM EST - 2 years ago

Company Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

AxoGen, Inc. (AXGN) Q3 2023 Earnings Call Transcript

Nov 7, 2023, 9:49 AM EST - 2 years ago

AxoGen, Inc. (AXGN) Q3 2023 Earnings Call Transcript

Axogen, Inc. Reports 2023 Third Quarter Financial Results

Nov 7, 2023, 7:00 AM EST - 2 years ago

Axogen, Inc. Reports 2023 Third Quarter Financial Results

AtomicAIerts
AtomicAIerts Dec. 5 at 9:58 AM
$AXGN AtomicAlerts Scalp Alert Direction: SHORT Entry: $32.86 TP1: $32.16 | TP2: $31.46 | TP3: $30.76 Stop Loss: $33.46 👉 https://atomicalerts.com
0 · Reply
Iightning
Iightning Dec. 5 at 5:16 AM
1ightning® Premium Options Alert (Actionable) Ticker: $AXGN Contract: Dec 19 $35C Entry: 1.48 Exit: 1.93 Return: +30.94% ROI Unlock VIP Access → https://1ightning.com
0 · Reply
Biobrocker12
Biobrocker12 Dec. 4 at 11:27 PM
$AXGN got the approval! I hope you like the free play $18->$33.50
0 · Reply
Iightning
Iightning Dec. 4 at 11:04 PM
1ightning® Premium Options Alert (Actionable) Ticker: $AXGN Contract: Dec 19 $35C Entry: 1.48 Exit: 1.93 Return: +30.94% ROI Unlock VIP Access → https://1ightning.com
0 · Reply
Doozio
Doozio Dec. 4 at 9:54 PM
$AXGN speaking of pullbahhhhhcks. All da way up da Roger YO go! It’s gonna get NUTX DAVE wen they all SEZL.
0 · Reply
JarvisFlow
JarvisFlow Dec. 4 at 7:39 PM
Jefferies has updated their rating for Axogen ( $AXGN ) to Buy with a price target of 36.
0 · Reply
CharlieeMungerTWITS
CharlieeMungerTWITS Dec. 4 at 7:04 PM
$AXGN GO GO GO!!!!
0 · Reply
JarvisFlow
JarvisFlow Dec. 4 at 6:03 PM
Lake Street updates rating for Axogen ( $AXGN ) to Buy, target set at 30 → 40.
0 · Reply
LuckEtradER
LuckEtradER Dec. 4 at 5:32 PM
$AXGN 🥰
0 · Reply
RunnerSignals
RunnerSignals Dec. 4 at 4:54 PM
Midday Buzz $SNCR $PATH $AXGN $ASTS $NUTX lighting up the trackers today. Deals approvals buybacks and momentum all colliding. Something big is brewing… worth a deeper look https://stocksrunner.com/news/2025-12-04-top-gainers-buzz-stocks-up-today-stock-market-movers
0 · Reply
Quantumup
Quantumup Dec. 4 at 4:39 PM
Jefferies⬆️ $AXGN's PT to $36 from $29 and reiterated at a Buy rating $SYK $BAX IART MDGX Mizuho reiterated at Outperform/$40 Raymond James⬆️PT to $36 from $27 and reiterated at an Outperform rating Citizens reiterated at a Market Outperform/$34 Here's what the Analysts had to say in their notes to investors:
0 · Reply
Tazdoc88
Tazdoc88 Dec. 4 at 4:33 PM
$AXGN
0 · Reply
dbr_island
dbr_island Dec. 4 at 4:30 PM
🚨EPOW🚨 loading here and can’t wait to show you my buys later once it runs BIG…… Just like QCLS 👇💰💰💰💰 $QURE $CEP $GNPX $AXGN $FRSX watching
0 · Reply
BenTheDo
BenTheDo Dec. 4 at 4:04 PM
$AXGN I predicated this move months ago hope y'll got the 200% gain I did!
0 · Reply
kgnfdeagle
kgnfdeagle Dec. 4 at 3:51 PM
$AXGN I am hodl as well.
0 · Reply
MikeyNJ
MikeyNJ Dec. 4 at 2:52 PM
$AXGN At this point, I just hold. I am thinking $42-$45 acquisition.
0 · Reply
kgnfdeagle
kgnfdeagle Dec. 4 at 2:51 PM
$AXGN Everyone wants a piece of the action now -- FOMO.
0 · Reply
dustin1101
dustin1101 Dec. 4 at 2:44 PM
$AXGN 2.6M shares short on the last update. Not huge but enough to move the stock a bunch. Not sure why anyone would continue to hold a short position now.
0 · Reply
topstockalerts
topstockalerts Dec. 4 at 2:27 PM
$AXGN setting up nicely.. 🏦
0 · Reply
djrktovod
djrktovod Dec. 4 at 1:59 PM
$AXGN $AXGN this product works..I’ve used it and it’s amazing for what it does for patients
0 · Reply
GetVector
GetVector Dec. 4 at 1:52 PM
Vector Intelligence (VI) is an algorithm designed to predict potential outsized intraday moves. VI will select up to 4 stocks per day. Today's VI stocks: $AXGN, $GCO, $PATH, $QURE.
0 · Reply
OpenOutcrier
OpenOutcrier Dec. 4 at 1:20 PM
$AXGN (+2.6% pre) Axogen receives FDA approval for AVANCE nerve allograft biologics license https://ooc.bz/l/86257
0 · Reply